OTC · VILGF
Yourgene Health Plc
$0.00$0.00 (0.0%)
Yourgene Health Plc: Healthcare · Medical - Diagnostics & Research.
Loading market information…
OTC · ATHJF · USD
Stock price, earnings
Quote as of Sep 13, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Antisense Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 84.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Antisense Therapeutics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Antisense Therapeutics Limited (ATHJF) is an Australian biotechnology company dedicated to the research and development of innovative antisense pharmaceuticals. Its therapeutic pipeline includes two primary drug candidates. ATL1102, an antisense inhibitor targeting CD49d, is currently in Phase II clinical trials for a variety of inflammatory conditions, such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. The company's second candidate, ATL1103, is an advanced second-generation antisense medication. This drug works by blocking growth hormone receptor expression, which subsequently lowers levels of insulin-like growth factor-I (IGF-I) in the bloodstream, and has successfully completed Phase II clinical trials for diseases linked to excessive growth hormone activity. Antisense Therapeutics Limited was established in 2000 and operates from its base in Toorak, Australia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Jun 30, 2021 |
| -$0.01+19.26% vs estimate |
| $278.64K |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Yourgene Health Plc: Healthcare · Medical - Diagnostics & Research.
$0.15-$0.01 (-8.96%)
Vinergy Capital Inc.’s quoted price sits in the upper half of its reported 52-week range, 48.39% below the high.
$0.16-$0.03 (-15.36%)
TPCO Holding Corp.’s quoted price sits in the lower half of its reported 52-week range, 83.81% below the high.
€2.94-€0.11 (-3.61%)
Biofrontera AG’s quoted price sits in the lower half of its reported 52-week range, 43.24% below the high.
$2.74-$0.01 (-0.27%)
Organicell Regenerative Medicine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
$0.21-$0.04 (-16.39%)
Simply Better Brands Corp.’s quoted price sits in the lower half of its reported 52-week range, 54.04% below the high.
₪1.90+₪0.05 (+2.7%)
Together Pharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 49.47% below the high.
$3.21-$0.10 (-3.02%)
Kadimastem Ltd’s quoted price sits in the lower half of its reported 52-week range, 64.61% below the high.
